Schedule III Lands & Sell The Cannabis News Remains Intact

The Department of Justice did it.

Acting Attorney General Todd Blanche signed an order today placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act, effective immediately. A separate expedited administrative hearing process kicks off June 29, 2026 to consider the broader Schedule III reclassification for marijuana generally. Anything outside an FDA-approved drug product or a qualifying state medical license stays in Schedule I.

This is the single most consequential federal cannabis policy action in decades. It’s also exactly the kind of binary catalyst the retail cannabis crowd has been praying for since 2014. And for anyone who has actually been paying attention to the tape, it lands inside a window that a specific voice on X has been mapping — publicly, repeatedly, and with receipts — for more than a decade.

The Seasonality Call Nobody Listened To

If you trade cannabis names and you aren’t following @WolfOfWeedST on X, you are trading the sector blindfolded.

Jason Spatafora — The Wolf of Weed Street — has been documenting the exact same seasonal playbook in cannabis since 2014. The framework, in his own words, on March 15, 2024:

Today is the #IdesOfMarch, since 2014 Cannabis space retail investors don’t know what it is or that the kick off is last week of February and it goes until July with pops last week of April & 1st week of May followed by worst parts in June.

And the tactical cheat sheet:

Pop last week of April 1st week of May, then fades until Last week of June, add. Ur welcome pop mid July, trim earnings, hold, trade 10% back and fourth into election. Trim before, dip, rip. Custody the key.

Read that again with today’s calendar in hand. Rescheduling announcement: April 23. Last week of April. The pop window Jason has been telegraphing for eleven straight years.

The “Sell the News” Pattern That Keeps Repeating

Skip ahead of you don’t want a history lesson

Cannabis has a cruel habit of delivering the catalyst and then immediately punishing everyone who chased the green candle. It happened on the original 2014 legalization runs. It happened on STATES Act headlines. It happened on the Biden HHS recommendation in August 2023. It happened on the DEA’s Schedule III proposal in May 2024. It happened on every SAFE/SAFER Banking vote cycle. It will, in all probability, happen again here.

Jason called each of those. Publicly. On the record. Before the prints. His July 2019 post warning about the Ides of March and scaling out of $ACB, $CGC, $HEXO, $TLRY, $TGOD, $APHA, $OGI, $TRUL, $LABS, $CXXI, $CBIS, $FI, $MJ, $HMMJ, $CTST, $CRON — that was a public top call. His 2018 note on summer volume disappearing and institutions waking up in September — documented. His 2021 thread laying out the full seasonality/Ides of March/volume framework going back to 2014 — archived, timestamped, receipts visible.

This is the part retail keeps missing: rescheduling is not a trade entry. It’s a liquidity event for the people who already bought the dip in June, July, and August of last year. The sellers on today’s spike are the tape-readers who have been accumulating quietly for months. The buyers are the headline-chasers who showed up when CNBC started running the chyron.

What Today Actually Means Mechanically

Schedule III removes the IRS Section 280E deduction blockade for holders of state medical marijuana licenses. Whitney Economics pegs the industry’s excess 280E tax burden since 2018 at roughly $15 billion. That is a real, durable earnings tailwind for the MSOs — Trulieve, Green Thumb, Curaleaf, Verano, Cresco — all of which have been trading like distressed debt for three years because their GAAP earnings were being eaten alive by a tax code written for heroin dealers.

The carve-out is also the tell. Anything not regulated by a state medical license or FDA-approved stays Schedule I. That keeps federal enforcement tools live against the illicit market, preserves political cover (“we’re not legalizing weed, we’re improving healthcare”), and specifically rewards the compliant, licensed operators who have spent years building out regulated supply chains. The June 29 hearing is the on-ramp for a broader industry-wide reschedule. Expect legal challenges from Smart Approaches to Marijuana — they’ve already telegraphed litigation.

Near-term tape will be violent in both directions. The initial pop is the shorts covering and the passive flows chasing. The second leg — if it comes — is the 280E refiling narrative and analyst upgrades once the tax math gets rerun. The fade — if Jason’s seasonal map holds — shows up somewhere between mid-May and the back half of June, right on schedule.

The Tape Already Told You

Here is the part that should stop every retail cannabis trader cold: the move already happened.

MSOS — the AdvisorShares Pure US Cannabis ETF, the cleanest sector proxy — ran roughly 28% into today’s announcement and was trading at a 20% premium to NAV heading into the print. Over the ten-day window around Trump’s December 18, 2025 executive order, Terrascend ran 69.62%, Curaleaf 57.94%, Cresco Labs 55.50%, Trulieve 53.73%, Tilray 53.75%, Canopy 35.34%. MSOS itself moved 44.99%. CNBS 46.32%.

Those are not “the catalyst is coming” moves. Those are “the catalyst is priced in” moves.

Then what happened? MSOS fell 34% off its August 2025 high of $5.57 into year-end redemptions. It fell 36.8% from the December 18 intraday high. Curaleaf dropped 1.4% into early 2026. Trulieve dropped 5.6%. The December spike exceeded the August 2024 HHS-recommendation volume and the late-2024 election plunge volume combined. Retail chased the headline. Institutions distributed. MSOS hit redemptions. The sector limped into 2026 trading like nothing ever happened.

And then came today’s April 23 pop — right in Jason’s last-week-of-April window, exactly as charted in the 2024 Ides of March post.

This is the pattern. Catalyst hits. Retail piles in at the top tick. Institutions sell into strength. The tape fades for weeks or months. The catalyst gets re-priced on the next headline. Lather, rinse, repeat. Every cannabis cycle since 2014 has rhymed.

The Receipts Going Back a Decade

Jason’s public track record on cannabis top-calls is not a story he tells himself. It is a public X archive with timestamps.

August 2019, 7/12/19 post: “Well you can’t say I’m not consistent with my warning of the Ides of March, if u look at the Han Solo tweet & u went PUTs to protect your neck then good job.” Tickers flagged in that post as being in the distribution phase: ACB, CGC, HEXO, TLRY, TGOD, APHA, OGI, TRUL, LABS, CXXI, CBIS, FI, MJ, HMMJ, CTST, CRON. Canopy was trading around $28 when he flagged it. By March 2020 it was under $12. Tilray went from $50+ in mid-2018 to under $3 by late 2019. Aphria, Aurora, HEXO — all cut to ribbons. Every single one of those names got smoked.

August 2014, 8/19/14 post: “This is my 5th summer trading potstocks and like a clockwork volume comes back… real companies go sideways and blast off in fall. U haven’t factored in Banks & big companies coming in now that it’s legal. The $STZ’s of the world I say.” That was him mapping the institutional accumulation window before anyone else in cannabis retail was thinking in those terms — and Constellation Brands (STZ) famously plowed $4 billion into Canopy Growth in August 2018, exactly as he’d projected the institutional flow would develop.

June 2018, 6/12/18 post: The framework held again. Summer fade, fall rip, institutional entry. He called the STZ-Canopy archetype four years before it printed.

March 2024, 3/15/24 Ides of March post: Mapped the exact 2024–2025 trading year. Pop late April / first week of May — happened. Worst parts in June — happened. Mid-July pop — happened. Trim into earnings, hold, trade the 10% chop into the November election — that is verbatim what the tape did. MSOS topped in August 2025 at $5.57, gave back 34% into year-end, then exploded higher into the December 18 EO. Institutional custody playing the framework. Retail eating the fade.

March 2019: “Make a mental note for 2019: October to March 15th and buy spring summer dips for #PotStocks.” That was the map. October 2019 lows held. March 2020 COVID crash wrecked everything, but anyone long cannabis into the April-July 2020 window caught Canopy from $14 to $30, Tilray from $3 to $10, Aphria from $3 to $8. The framework worked even through a black swan.

This is eleven years of public, timestamped, directionally-correct cannabis seasonality calls. Name another voice in the space with that archive.

The Playbook From Here

Schedule III is real. 280E relief is real. The hearing on June 29 is real. None of that changes the seasonal physics.

Jason’s 2024 cheat sheet, applied to right now:

• Late April / first week of May: pop. (We’re in it.)

• Mid-May through last week of June: fade. Trim into strength. Accumulate the dip at the bottom of the range.

• Last week of June: add. This is the setup window.

• Mid-July: pop. This is where the 280E refiling narrative, Q2 earnings with cleaner tax math, and the Schedule III hearing outcome collide.

• Earnings (Q2 prints August): trim.

• Fall into election cycle (midterms 2026): 10% chop, trade both sides.

• Custody is the key. Own the shares outright. Options are for the nimble and dangerous for the distracted.

The MSO names with the cleanest 280E setup are the ones with legitimate state medical licenses and the scale to actually capture the tax benefit: Trulieve (TCNNF), Green Thumb (GTBIF), Curaleaf (CURLF), Verano (VRNOF), Cresco (CRLBF). Second-order beneficiary is IIPR — as operators’ margins improve, lease renewals and new capex commitments get easier, and IIPR is the landlord. Canadian LPs (Tilray, Canopy) trade on the headline correlation but don’t get the direct 280E benefit — they were already exempt.

The names that don’t have state medical licenses and aren’t FDA-approved drug products? Still Schedule I. Still paying 280E. Still watching the institutional flows go somewhere else. That list is long and mostly includes the OTC penny names retail loves to pump.

Why This Track Record Matters

Anyone can call a bottom in a bull market. The thing that separates a real cannabis strategist from the Twitter noise is the ability to call the top — to tell the audience to trim into strength when every other account is screaming “to the moon.” That is what Jason has done, cycle after cycle, since 2014. Ides of March. Summer fade. Fall accumulation. Winter catalyst chase. Rinse. Repeat.

Today’s Schedule III announcement does not invalidate the seasonal map. It confirms it. The policy catalyst landed inside the exact window he’s been flagging publicly for eleven years. The pre-news run already happened. The sell-the-news fade is the next scheduled print. The question for every cannabis investor long the sector right now is whether you want to be the person who followed the framework — or the person who showed up at the top because a DOJ press release hit your feed at 10 a.m. Eastern.

Follow @WolfOfWeedST. Read the archive. Map the calendar. And the next time a cannabis catalyst prints right in the window he’s been drawing on the chart for over a decade, stop acting surprised.